AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03402789
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet daily plus 2 hours of eye patching daily
Trial: NCT04930796
Drug: VER-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)
Trial: NCT05236634
Drug: Alpha Blockers
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
Trial: NCT05236634
Drug: Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
Trial: NCT04816253
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline irrigation and No other drug placed after extraction
Trial: NCT04816253
Drug: Methylprednisolone and Hyaluronic acid
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone will be injected half an hour preoperatively and Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
Trial: NCT05017480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous(SC) injection
Trial: NCT05426889
Drug: drug conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient did not receive surgical treatment and chose conservative treatment
Trial: NCT06407297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral intravenous infusion of Placebo
Trial: NCT04820972
Drug: Antiplatelet Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: using antiplatelet agents in 3 days after surgery
Trial: NCT06246565
Drug: HS-10383 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
Trial: NCT06490913
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, bid, d1-d14，q3w，1cycle
Trial: NCT06490913
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m2, d1,q2w
Trial: NCT05727644
Drug: NNC0194-0499
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
Trial: NCT05506007
Drug: DA-5216-R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8.
Trial: NCT06265675
Drug: Phenol
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemical neurolysis
Trial: NCT05284409
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 patients will receive 15 mg/kg Acetaminophen IVI
Trial: NCT05099133
Drug: LEO 138559
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEO 138559 is an antibody given by injection just under the skin.
Trial: NCT05967299
Drug: ZMA001 (BC-NKA-20008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH).
Trial: NCT05005806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo soft gel
Trial: NCT05112536
Drug: Cylophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
Trial: NCT05112536
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin administered as an IV bolus every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
Trial: NCT05111444
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of XELOX chemotherapy regimen
Trial: NCT00199277
Drug: i.v. iron sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00199277
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04972396
Drug: Ethinylestradiol and Levonorgestrel
RxNorm normalized name: Ethinylestradiol and levonorgestrel only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken by mouth (PO)
Trial: NCT06144918
Drug: SBI-100 Ophthalmic Emulsion, 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
Trial: NCT06144918
Drug: SBI-100 Ophthalmic Emulsion, 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
Trial: NCT06144918
Drug: SBI-100 Ophthalmic Emulsion, Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, SBI-100 Ophthalmic Emulsion eyedrop without the active ingredient (SBI-100)
Trial: NCT06278077
Drug: Neurexan
RxNorm normalized name: Coffea arabica/Common Oat/Passiflora incarnata/Zincum Valerianicum 12 X/0.6 MG-2 X/0.6 MG-2 X/0.6 MG-4 X/0.6 MG Sublingual Tablet [NEUREXAN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active ingredients are Passiflora incarnata Dil. D2 (0.6 mg / tablet), Avena sativa Dil. D2 (0.6 mg / tablet), Coffea arabica Dil. D12 (0.6 mg/tablet) and Zincum isovalerianicum Dil. D4 (0.6 mg / tablet). Inactive excipients are lactose monohydrate and magnesium stearate.
Trial: NCT06278077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains lactose monohydrate, magnesium stearate and looks identical to Neurexan in terms of taste, size, color and labelling.
Trial: NCT06535568
Drug: Single antiplatelet therapy (SAPT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The antithrombotic regimen is single antiplatelet therapy (SAPT). The Investigator will decide if to use aspirin or clopidogrel, whereas ticagrelor or prasugrel are not recommended in our study population since no benefit (or even harm) has been shown by these drugs in head-to-head trials versus clopidogrel in elderly PCI populations. The type of agent and treatment duration will be selected according to the clinical characteristics of the patient.
Trial: NCT05113693
Drug: CKD-501, D759, H053
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT05155202
Drug: Antihypertensive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of intravenous Nicardipine or Urapidil
Trial: NCT04678882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
Trial: NCT04579523
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05137067
Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05137067
Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Trial: NCT05182463
Drug: Nucleoside Analogs
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
Trial: NCT05879653
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the induction phase, MK-3475 200 mg will be administered as four cycles of 3-weeks regimen, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle. The treatment and maintenance phases will consist of 9 cycles of one course per 6 weeks, with MK-3475 400 mg administered on Day 1 of each course at Q6W.
Trial: NCT05879653
Drug: ASG-22CE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the induction phase, four cycles of 3-weeks regimen are administered, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle.
Trial: NCT05722782
Drug: Piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 20 mg piroxicam per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
Trial: NCT05722782
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 1000 mg Acetaminophen per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
Trial: NCT05722782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
Trial: NCT05565742
Drug: LY3819469
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05565742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05970640
Drug: Placebo matching BI 3006337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 3006337
Trial: NCT06383078
Drug: HR070803
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR070803 60 mg/\^2 D1 over 90 minutes.
Trial: NCT06660290
Drug: 0.003% AR-15512 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational ophthalmic solution for topical instillation
Trial: NCT06660290
Drug: REFRESH® Classic ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available ophthalmic solution for topical instillation
Trial: NCT04551261
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. It is HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection;~2. It is a CYP3A inhibitor combined with other drug to increase the exposure in human.
Trial: NCT04551261
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
Trial: NCT06196515
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
Trial: NCT06196515
Drug: nano calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
Trial: NCT06492122
Drug: [225Ac]Ac-FL-020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[225Ac\]Ac-FL-020 injected intravenously
Trial: NCT06492122
Drug: Blood samples for PK
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the first injection of \[225Ac\]Ac-FL-020, blood samples after treatment will be collected for PK evaluation.
Trial: NCT06492122
Drug: [111In]In-FL-020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of \[111In\]In-FL-020 will be injected prior to the first dose of \[225Ac\]Ac-FL-020 for dosimetry evaluation
Trial: NCT04666714
Drug: Praga formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praga formulation tablet
Trial: NCT04945070
Drug: IGlarLixi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching T2DM subjects from MDI to iGlarLixi
Trial: NCT04721795
Drug: Standard anti tuberculosis drugs only
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
Trial: NCT04881461
Drug: 5-grass mix SLIT-drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual allergy immunotherapy drops, for daily administration
Trial: NCT04881461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04937387
Drug: FF/UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/UMEC/VI will be administered.
Trial: NCT04484142
Drug: DS-1062a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks
Trial: NCT06441097
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT06441097
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT00001014
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05023486
Drug: Anti-PD-1 Therapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: previously initiated per standard of care, at a dose and frequency in accordance with the package insert
Trial: NCT04719650
Drug: Zoledronic Acid Injection
RxNorm normalized name: zoledronic acid Injection
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Infusion 1mg zoledronic acid once.
Trial: NCT04719650
Drug: Zoledronic Acid Injection
RxNorm normalized name: zoledronic acid Injection
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Infusion 2.5mg zoledronic acid once.
Trial: NCT04719650
Drug: Zoledronic Acid Injection
RxNorm normalized name: zoledronic acid Injection
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Infusion 5mg zoledronic acid once.
Trial: NCT04719650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion normal saline once.
Trial: NCT04904120
Drug: [203Pb]VMT01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic imaging radiopharmaceutical; by intravenous infusion
Trial: NCT04904120
Drug: [68Ga]VMT02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic imaging radiopharmaceutical; by intravenous infusion
Trial: NCT05062200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as an oral tablet.
Trial: NCT06178523
Drug: Clomiphene Citrate.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle (Groups A, B, and C).
Trial: NCT06006247
Drug: CVN424 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 CVN424 tablet (150 mg) per day.
Trial: NCT06006247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 matching placebo tablet per day.
Trial: NCT05038020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo
Trial: NCT04661709
Drug: WXG placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one dose daily, two times per day.
Trial: NCT06451783
Drug: Celecoxib capsule
RxNorm normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Celecoxib Capsules, 200mg per dose, once daily after lunch.
Trial: NCT06024642
Drug: V117957
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V117957 1 mg - 1 tablet taken orally at bedtime.
Trial: NCT06024642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
Trial: NCT06548919
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All endocrine treatment regimens approved for advanced breast cancer, including tamoxifen, aromatase inhibitors, fulvestrant, etc.
Trial: NCT05639127
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulization of prednisolone
Trial: NCT00025051
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05203497
Drug: SPECT
RxNorm normalized name: Spectrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single injection of 99mTc-ZHER2:41071, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
Trial: NCT06563271
Drug: Dexketoprofen Trometamol 50 Mg/mL Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen 50 mg administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
Trial: NCT06563271
Drug: Ibuprofen 100 MG/ML Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 100 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).~Group P: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
Trial: NCT06563271
Drug: Paracetamol 10 Mg/mL Solution for Injection
RxNorm normalized name: Paracetamol 10 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
Trial: NCT06563271
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and dexketoprofen will be administered intravenously (IV) by mixing them into 150 cc of isotonic saline.
Trial: NCT05240911
Drug: Levothyroxine Sodium Tablets
RxNorm normalized name: Levothyroxine Sodium Tablets
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For patients in experimental group, initial levothyroxine dose is calculated through the Poisson regression model; and for patients in comparator group, initial levothyroxine dose is calculated through 1.6 ug/kg/d.
Trial: NCT05528354
Drug: VEN and DEC based conditioning regimen
RxNorm normalized name: Apis mellifera ven protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with age\<50 years and HCT-CI\<3:~Haploidentical transplantation: AraC 2g/m2 d-10\~d-9, BU 0.8mg/kg q6h d-8\~-6, CTX 1.8g/m2 d-5\~d-4, Meccnu 250mg/m2 d-3, ATG 1.5mg/kg/d d-5\~-2, VEN 400mg/d d-15\~-9, DEC 20mg/m2 d-15\~-11; HLA-matched transplantation: BU 0.8mg/kg q6h d-7\~-4, CTX 60mg/kg d-3\~d-2, Meccnu 250mg/m2 d-1, VEN d-12\~-8, DEC 20mg/m2 d-12\~-6, and ATG for the unrelated donor type.~Patients with age\>50 years or HCT-CI≥3:~Flu 30mg/m2 d-10\~-5, BU 0.8mg/kg q6h d-7\~-5, Meccnu 250mg/m2 d-4, ATG 7.5mg/kg divided into d-4\~-1, VEN d-15\~-9, DEC 20mg/m2 d-15\~-11.~Note: if Voriconazole or Posaconazole is used to prevent or treat fungal infections, VEN should be 200mg/d for 7 consecutive days.
Trial: NCT05748977
Drug: SABA SAMA ICS Vs LABA LAMA ICs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short acting agents,long acting agents ,ics
Trial: NCT04887480
Drug: Dianeal PD-2 with 2.5% Dextrose
RxNorm normalized name: Dianeal PD-2 with 2.5% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800mL to 1000mL of Dianeal PD-2 into Abthera™ and dwell for 1 hour.
Trial: NCT04688736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The tablet resembles chlorpheniramine but has no therapeutic value.
Trial: NCT05133817
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.